{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:34:51Z","timestamp":1772724891375,"version":"3.50.1"},"reference-count":101,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Lancet Neurology"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1016\/s1474-4422(04)00769-0","type":"journal-article","created":{"date-parts":[[2004,5,25]],"date-time":"2004-05-25T17:02:03Z","timestamp":1085504523000},"page":"362-368","source":"Crossref","is-referenced-by-count":50,"title":["Disease modification in Parkinson's disease"],"prefix":"10.1016","volume":"3","author":[{"given":"Anthony HV","family":"Schapira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S1474-4422(04)00769-0_bib1","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1212\/WNL.46.5.1275","article-title":"Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany","volume":"46","author":"Seidler","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(04)00769-0_bib2","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1212\/WNL.40.8.1218","article-title":"Environmental risk factors in Parkinson's disease","volume":"40","author":"Koller","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(04)00769-0_bib3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1017\/S0317167100031826","article-title":"Parkinson's disease and exposure to rural environmental factors: a population based case-control study","volume":"18","author":"Semchuk","year":"1991","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/S1474-4422(04)00769-0_bib4","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/81834","article-title":"Chronic systemic pesticide exposure reproduces features of Parkinson's disease","volume":"3","author":"Betarbet","year":"2000","journal-title":"Nat Neurosci"},{"key":"10.1016\/S1474-4422(04)00769-0_bib5","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1074\/jbc.C100560200","article-title":"The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein","volume":"277","author":"Manning-Bog","year":"2002","journal-title":"Biol Chem"},{"key":"10.1016\/S1474-4422(04)00769-0_bib6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1471-4159.2003.02138.x","article-title":"Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe","volume":"88","author":"Champy","year":"2004","journal-title":"J Neurochem"},{"key":"10.1016\/S1474-4422(04)00769-0_bib7","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/j.1471-4159.1993.tb13610.x","article-title":"Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds","volume":"61","author":"Tipton","year":"1993","journal-title":"J Neurochem"},{"key":"10.1016\/S1474-4422(04)00769-0_bib8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1017\/S0317167100026147","article-title":"Ecogenetics of Parkinson's disease: prevalence and environmental aspects in rural areas","volume":"14","author":"Barbeau","year":"1987","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/S1474-4422(04)00769-0_bib9","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1017\/S0317167100037823","article-title":"Geography, drinking water chemistry, pesticides, and herbicides and the etiology of Parkinson's disease","volume":"14","author":"Rajput","year":"1987","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/S1474-4422(04)00769-0_bib10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/mds.870070209","article-title":"Exposure to well water and pesticides in Parkinson's disease: a case-control study in the Madrid area","volume":"7","author":"Jim\u00e9nez-Jim\u00e9nez","year":"1992","journal-title":"Mov Disord"},{"key":"10.1016\/S1474-4422(04)00769-0_bib11","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1212\/WNL.36.11.1490","article-title":"Cigarette smoking and Parkinson's disease","volume":"36","author":"Baron","year":"1986","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(04)00769-0_bib12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ana.1052","article-title":"Prospective study of caffeine consumption and risk of Parkinson's disease in men and women","volume":"50","author":"Ascherio","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/S1474-4422(04)00769-0_bib13","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1212\/WNL.38.8.1285","article-title":"Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains","volume":"38","author":"McGeer","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(04)00769-0_bib14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0304-3940(94)90684-X","article-title":"Immunohistochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease","volume":"172","author":"Boka","year":"1994","journal-title":"Neurosci Lett"},{"key":"10.1016\/S1474-4422(04)00769-0_bib15","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1523\/JNEUROSCI.19-09-03440.1999","article-title":"FcepsilonRII\/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-in glial cells","volume":"19","author":"Hunot","year":"1999","journal-title":"J Neurosci"},{"key":"10.1016\/S1474-4422(04)00769-0_bib16","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1212\/WNL.47.2.425","article-title":"Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies","volume":"47","author":"McGeer","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(04)00769-0_bib17","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1056\/NEJMoa010178","article-title":"Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease","volume":"345","author":"In t' Veld","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/S1474-4422(04)00769-0_bib18","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/archneur.60.8.1059","article-title":"Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease","volume":"60","author":"Chen","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/S1474-4422(04)00769-0_bib19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/jama.281.4.341","article-title":"Parkinson disease in twins: an etiologic study","volume":"281","author":"Tanner","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/S1474-4422(04)00769-0_bib20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/1531-8249(199905)45:5<577::AID-ANA5>3.0.CO;2-O","article-title":"The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins","volume":"45","author":"Piccini","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1016\/S1474-4422(04)00769-0_bib21","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1002\/ana.10487","article-title":"Genetic and environmental factors in the cause of Parkinson's disease","volume":"53","author":"Warner","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/S1474-4422(04)00769-0_bib22","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson's disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"10.1016\/S1474-4422(04)00769-0_bib23","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ng0298-106","article-title":"Ala39Pro mutation in the gene encoding \u03b1 synuclein in Parkinson's disease","volume":"18","author":"Kr\u00fcger","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/S1474-4422(04)00769-0_bib24","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1090278","article-title":"Alpha-Synuclein locus triplication causes Parkinson's disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"key":"10.1016\/S1474-4422(04)00769-0_bib25","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ana.10846","article-title":"Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications","volume":"55","author":"Farrer","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/S1474-4422(04)00769-0_bib26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ana.10795","article-title":"The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia","volume":"55","author":"Zarranz","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/S1474-4422(04)00769-0_bib27","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/S1474-4422(04)00769-0_bib28","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/33416","article-title":"Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism","volume":"392","author":"Kitada","year":"1998","journal-title":"Nature"},{"key":"10.1016\/S1474-4422(04)00769-0_bib29","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/77060","article-title":"Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase","volume":"25","author":"Shimura","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/S1474-4422(04)00769-0_bib30","doi-asserted-by":"crossref","first-page":"13354","DOI":"10.1073\/pnas.240347797","article-title":"Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1","volume":"97","author":"Zhang","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S1474-4422(04)00769-0_bib31","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/26652","article-title":"The ubiquitin pathway in Parkinson's disease","volume":"395","author":"Leroy","year":"1998","journal-title":"Nature"},{"key":"10.1016\/S1474-4422(04)00769-0_bib32","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0304-3940(00)01701-8","article-title":"Proteasomal function is impaired in substantia nigra in Parkinson's disease","volume":"297","author":"McNaught","year":"2001","journal-title":"Neurosci Lett"},{"key":"10.1016\/S1474-4422(04)00769-0_bib33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1006\/exnr.2002.8050","article-title":"Altered proteasomal function in Parkinson's disease","volume":"179","author":"McNaught","year":"2003","journal-title":"Exp Neurol"},{"key":"10.1016\/S1474-4422(04)00769-0_bib34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0896-6273(00)80886-7","article-title":"Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system","volume":"25","author":"Abeliovich","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/S1474-4422(04)00769-0_bib35","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1126\/science.287.5456.1265","article-title":"Dopaminergic loss and inclusion body formation in \u03b1-synuclein mice: implications for neurodegenerative disorders","volume":"287","author":"Masliah","year":"2000","journal-title":"Science"},{"key":"10.1016\/S1474-4422(04)00769-0_bib36","first-page":"451","article-title":"A Drosophila model of Parkinson's disease","volume":"101","author":"Feany","year":"2000","journal-title":"Nature"},{"key":"10.1016\/S1474-4422(04)00769-0_bib37","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0896-6273(02)00682-7","article-title":"Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein","volume":"34","author":"Giasson","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/S1474-4422(04)00769-0_bib38","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0896-6273(01)00462-7","article-title":"Beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor","volume":"32","author":"Hashimoto","year":"2001","journal-title":"Neuron"},{"key":"10.1016\/S1474-4422(04)00769-0_bib39","doi-asserted-by":"crossref","first-page":"43628","DOI":"10.1074\/jbc.M308947200","article-title":"Parkin-deficient mice exhibit nigrostriatal deficits but no loss of dopaminergic neurons","volume":"278","author":"Goldberg","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/S1474-4422(04)00769-0_bib40","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0092-8674(00)81782-1","article-title":"Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions","volume":"95","author":"Saudou","year":"1998","journal-title":"Cell"},{"key":"10.1016\/S1474-4422(04)00769-0_bib41","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1073\/pnas.97.2.571","article-title":"Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy","volume":"97","author":"Conway","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S1474-4422(04)00769-0_bib42","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1126\/science.1063522","article-title":"Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct","volume":"294","author":"Conway","year":"2001","journal-title":"Science"},{"issue":"suppl 3","key":"10.1016\/S1474-4422(04)00769-0_bib43","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1002\/ana.10479","article-title":"Bioenergetic approaches for neuroprotection in Parkinson's disease","volume":"53","author":"Beal","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/S1474-4422(04)00769-0_bib44","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1087753","article-title":"Molecular pathways of neurodegeneration in Parkinson's disease","volume":"302","author":"Dawson","year":"2003","journal-title":"Science"},{"key":"10.1016\/S1474-4422(04)00769-0_bib45","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1146\/annurev.biochem.68.1.1015","article-title":"The 26S proteasome: a molecular machine designed for controlled proteolysis","volume":"68","author":"Voges","year":"1999","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/S1474-4422(04)00769-0_bib46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1097-2765(02)00775-X","article-title":"ATP hydrolysis by the proteasome regulatory complex PAN serves multiple functions in protein degradation","volume":"11","author":"Benaroudj","year":"2003","journal-title":"Mol Cell"},{"key":"10.1016\/S1474-4422(04)00769-0_bib47","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1046\/j.1471-4159.2003.01952.x","article-title":"Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease","volume":"86","author":"Hoglinger","year":"2003","journal-title":"J Neurochem"},{"key":"10.1016\/S1474-4422(04)00769-0_bib48","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1056\/NEJM199301213280305","article-title":"Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease","volume":"328","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/S1474-4422(04)00769-0_bib49","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.410380512","article-title":"The effect of deprenyl and levodopa on the progression of signs and symptoms in Parkinson's disease","volume":"38","author":"Olanow","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/S1474-4422(04)00769-0_bib50","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ana.10191","article-title":"Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease:a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial","volume":"51","author":"Shoulson","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1016\/S1474-4422(04)00769-0_bib51","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0140-6736(89)92366-0","article-title":"Mitochondrial complex I deficiency in Parkinson's disease","volume":"1","author":"Schapira","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/S1474-4422(04)00769-0_bib52","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/ana.410420221","article-title":"Coenzyme Q10 levels correlate with the activities of complexes I and II\/III in mitochondria from parkinsonian and nonparkinsonian subjects","volume":"42","author":"Shults","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/S1474-4422(04)00769-0_bib53","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archneur.59.10.1541","article-title":"Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline 307","volume":"59","author":"Shults","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/S1474-4422(04)00769-0_bib54","first-page":"39","article-title":"A 2-year multicenter placebo-contolled, double-blind, parallel group study of the effect of riluzole on Parkinson's disease progression","volume":"17","author":"Rascol","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/S1474-4422(04)00769-0_bib55","doi-asserted-by":"crossref","first-page":"9808","DOI":"10.1073\/pnas.90.21.9808","article-title":"Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity","volume":"90","author":"Dawson","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S1474-4422(04)00769-0_bib56","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ana.1030","article-title":"Neuroimmunophilins: novel neuroprotective and neuroregenerative targets","volume":"50","author":"Guo","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/S1474-4422(04)00769-0_bib57","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/archneur.60.3.369","article-title":"Caspase gene expression in the brain as a function of the clinical progression of Alzheimer disease","volume":"60","author":"Pompl","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/S1474-4422(04)00769-0_bib58","series-title":"Motor neuron disorders","first-page":"357","article-title":"Pathology of motor neuron disorders","author":"Przedborski","year":"2003"},{"key":"10.1016\/S1474-4422(04)00769-0_bib59","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/77528","article-title":"Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease","volume":"6","author":"Chen","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/S1474-4422(04)00769-0_bib60","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/ana.10614","article-title":"Minocycline and doxycycline are not beneficial in a model of Huntington's disease","volume":"54","author":"Smith","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/S1474-4422(04)00769-0_bib61","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/80538","article-title":"Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease","volume":"6","author":"Chen","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/S1474-4422(04)00769-0_bib62","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/417074a","article-title":"Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice","volume":"417","author":"Zhu","year":"2002","journal-title":"Nature"},{"key":"10.1016\/S1474-4422(04)00769-0_bib63","doi-asserted-by":"crossref","first-page":"14014","DOI":"10.1073\/pnas.93.24.14014","article-title":"A novel mechanism of action of tetracyclines: effects on nitric oxide synthases","volume":"93","author":"Amin","year":"1996","journal-title":"Proc Natl Acad USA"},{"key":"10.1016\/S1474-4422(04)00769-0_bib64","doi-asserted-by":"crossref","first-page":"15769","DOI":"10.1073\/pnas.95.26.15769","article-title":"Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia","volume":"95","author":"Yrjanheikki","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S1474-4422(04)00769-0_bib65","doi-asserted-by":"crossref","first-page":"14669","DOI":"10.1073\/pnas.251341998","article-title":"Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease","volume":"98","author":"Du","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S1474-4422(04)00769-0_bib66","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0006-8993(01)02681-6","article-title":"Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum","volume":"909","author":"He","year":"2001","journal-title":"Brain Res"},{"key":"10.1016\/S1474-4422(04)00769-0_bib67","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1523\/JNEUROSCI.21-08-02580.2001","article-title":"Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia","volume":"21","author":"Tikka","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/S1474-4422(04)00769-0_bib68","doi-asserted-by":"crossref","first-page":"7527","DOI":"10.4049\/jimmunol.166.12.7527","article-title":"Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia","volume":"166","author":"Tikka","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/S1474-4422(04)00769-0_bib69","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1523\/JNEUROSCI.22-05-01763.2002","article-title":"Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease","volume":"22","author":"Wu","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/S1474-4422(04)00769-0_bib70","doi-asserted-by":"crossref","first-page":"14669","DOI":"10.1073\/pnas.251341998","article-title":"Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease","volume":"98","author":"Du","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S1474-4422(04)00769-0_bib71","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/jnr.10709","article-title":"Minocycline enhances MPTP toxicity to dopaminergic neurons","volume":"74","author":"Yang","year":"2003","journal-title":"J Neurosci Res"},{"key":"10.1016\/S1474-4422(04)00769-0_bib72","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1001\/archneur.59.12.1937","article-title":"A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study","volume":"59","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/S1474-4422(04)00769-0_bib73","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1046\/j.1471-4159.2002.01047.x","article-title":"Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan","volume":"82","author":"Akao","year":"2002","journal-title":"J Neurochem"},{"key":"10.1016\/S1474-4422(04)00769-0_bib74","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.1074\/jbc.273.10.5821","article-title":"Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl","volume":"273","author":"Kragten","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/S1474-4422(04)00769-0_bib75","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa","volume":"342","author":"Rascol","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/S1474-4422(04)00769-0_bib76","first-page":"231","article-title":"Pramipexole vs levodopa as initial treatment for Parkinson disease","volume":"284","year":"2000","journal-title":"JAMA"},{"issue":"suppl 1","key":"10.1016\/S1474-4422(04)00769-0_bib77","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00003495-199855001-00004","article-title":"Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications: results of a double-blind levodopa controlled trial","volume":"55","author":"Rinne","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/S1474-4422(04)00769-0_bib78","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1002\/ana.10514","article-title":"Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease","volume":"53","author":"Schapira","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/S1474-4422(04)00769-0_bib79","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1212\/WNL.61.6_suppl_3.S34","article-title":"Neuroprotection in PD-a role for dopamine agonists?","volume":"61","author":"Schapira","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(04)00769-0_bib80","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00002512-200118060-00001","article-title":"Are dopamine receptor agonists neuroprotective in Parkinson's disease?","volume":"18","author":"Le","year":"2001","journal-title":"Drugs Aging"},{"key":"10.1016\/S1474-4422(04)00769-0_bib81","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1046\/j.1468-1331.9.s3.9.x","article-title":"Dopamine agonists and neuroprotection in Parkinson's disease","volume":"3","author":"Schapira","year":"2002","journal-title":"Eur J Neurol"},{"key":"10.1016\/S1474-4422(04)00769-0_bib82","first-page":"377","article-title":"Pramipexole protects against MPP+ toxicity in SHSY5Y cells by maintaining mitochondrial membrane potential","volume":"56","author":"King","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(04)00769-0_bib83","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1471-4159.1998.71010295.x","article-title":"Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion","volume":"71","author":"Cassarino","year":"1998","journal-title":"J Neurochem"},{"key":"10.1016\/S1474-4422(04)00769-0_bib84","first-page":"494","article-title":"Pramipexole protects against MPTP-induced nigral dopaminergic cell loss in primates","volume":"58","author":"Jenner","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(04)00769-0_bib85","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.287.13.1653","article-title":"Dopamine transporter brain imaging to assess the effects of Pramipexole vs levodopa Parkinson's disease progression","volume":"287","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/S1474-4422(04)00769-0_bib86","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ana.10609","article-title":"Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study","volume":"54","author":"Whone","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/S1474-4422(04)00769-0_bib87","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/jnnp.64.3.314","article-title":"Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F}dopa PET","volume":"64","author":"Morrish","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/S1474-4422(04)00769-0_bib88","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/1531-8249(200006)47:6<804::AID-ANA14>3.0.CO;2-F","article-title":"Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand[18F}CFT","volume":"47","author":"Nurmi","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/S1474-4422(04)00769-0_bib89","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/mds.1265","article-title":"Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal \u03b2-CIT SPECT study","volume":"17","author":"Pirker","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/S1474-4422(04)00769-0_bib90","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/ana.410340304","article-title":"Human positron emission tomographic [18]flourodopa studies correlate with dopamine cell counts and levels","volume":"34","author":"Snow","year":"1993","journal-title":"Ann Neurol"},{"key":"10.1016\/S1474-4422(04)00769-0_bib91","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jama.291.3.358","article-title":"Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions","volume":"291","author":"Schapira","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/S1474-4422(04)00769-0_bib92","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/01.WNL.0000044047.58984.2F","article-title":"Slowing Parkinson's disease progression: recent dopamine agonist trials","volume":"60","author":"Ahlskog","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(04)00769-0_bib93","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/mds.10448","article-title":"REAL and CALM: what have we learned?","volume":"18","author":"Morrish","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/S1474-4422(04)00769-0_bib94","first-page":"S13","article-title":"Clinical trials in movement disorders","volume":"17","author":"Fahn","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/S1474-4422(04)00769-0_bib95","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJM200103083441002","article-title":"Transplantation of embryonic dopamine neurons for severe Parkinson's disease","volume":"344","author":"Freed","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/S1474-4422(04)00769-0_bib96","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.10720","article-title":"A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease","volume":"54","author":"Olanow","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/S1474-4422(04)00769-0_bib97","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/brain\/awf234","article-title":"Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys","volume":"125","author":"Grondin","year":"2002","journal-title":"Brain"},{"key":"10.1016\/S1474-4422(04)00769-0_bib98","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1126\/science.290.5492.767","article-title":"Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease","volume":"290","author":"Kordower","year":"2000","journal-title":"Science"},{"key":"10.1016\/S1474-4422(04)00769-0_bib99","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q","article-title":"Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease","volume":"46","author":"Kordower","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1016\/S1474-4422(04)00769-0_bib100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1212\/WNL.60.1.69","article-title":"ICV GDNF Study Group. Implanted intracerebroventricular Glial cell line-derived neurotrophic factor: randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD","volume":"60","author":"Nutt","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(04)00769-0_bib101","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm850","article-title":"Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease","volume":"9","author":"Gill","year":"2003","journal-title":"Nat Med"}],"container-title":["The Lancet Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1474442204007690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1474442204007690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T20:58:51Z","timestamp":1549573131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1474442204007690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":101,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["S1474442204007690"],"URL":"https:\/\/doi.org\/10.1016\/s1474-4422(04)00769-0","relation":{},"ISSN":["1474-4422"],"issn-type":[{"value":"1474-4422","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}